Comparison of the effect of 5% minoxidil and topical epinephrine on the prevention of chemotherapy-induced hair loss in patients with breast cancer compared to the control group (placebo recipients) in 1398-1399

Comparison of the effect of 5% minoxidil and topical epinephrine on the prevention of chemotherapy-induced hair loss in patients with breast cancer compared to the control group (placebo recipients)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200205046380N1

Enrollment

Registered

2020-03-16

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced hair loss.

Interventions

Intervention 1: The first intervention group will receive 1 ml of 5% minoxidil prepared by Shahid Beheshti Pharmacology Group twice a day. Intervention 2: The second intervention group will receive 1

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with breast cancer referred to Shohadaye Tajrish Hospital for chemotherapy including adriamycin, cyclophosphamide, and taxol in 2020-2021 Informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Presence of metastasis Presence of inflammatory scalp diseases Patients with other causes of hair loss including telogen effluvium, lichen planopilaris, and discoid lupus erythematosus Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
The evaluation of anagen hair count in trichoscopic findings of patients. Timepoint: The first time, the second or third time, the last time and one month after chemotherapy. Method of measurement: FotoFinder device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhetere Zahedi

Shahid Beheshti University of Medical Sciences

khaterezahedi4819@gmail.com002188045103

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026